Pfizer Inc.PFENYSE
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +31.21% | +21.91% | -7.82% | +10.31% | -5.92% |
| Gross Profit Growth | +272.96% | +116.86% | -6.39% | +14.28% | +15.89% |
| EBITDA Growth | +0.00% | +0.00% | -15.00% | +121.33% | -22.13% |
| Operating Income Growth | +0.00% | +0.00% | +1.43% | +90.26% | -28.54% |
| Net Income Growth | +0.00% | +0.00% | -4.90% | +12025.00% | -20.84% |
| EPS Growth | +0.00% | +0.00% | -5.20% | +12042.86% | -21.45% |
| EPS Diluted Growth | +0.00% | +0.00% | -5.13% | +12042.86% | -20.92% |
| Weighted Average Shares Growth | +0.37% | +0.35% | +0.32% | +0.34% | +0.32% |
| Weighted Average Shares Diluted Growth | +1.04% | +0.99% | +0.23% | +0.18% | +0.16% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +94.27% | +28.26% | +114.22% | +0.00% | -31.44% |
| Free Cash Flow Growth | +129.14% | +38.32% | +358.81% | +0.00% | -34.01% |
| Receivables Growth | +17.94% | -4.93% | +0.00% | -19.94% | -19.41% |
| Inventory Growth | +14.87% | +6.50% | +0.00% | +1.94% | -2.16% |
| Asset Growth | +2.07% | -5.79% | +0.00% | -4.67% | -4.90% |
| Book Value per Share Growth | -5.15% | -1.26% | +0.00% | +0.80% | +0.24% |
| Debt Growth | +4.75% | -10.16% | +0.00% | -10.02% | -7.36% |
| R&D Expense Growth | -4.36% | +8.80% | -12.14% | -8.71% | +53.45% |
| SG&A Expenses Growth | +0.81% | -5.46% | -12.58% | -7.75% | -1.61% |